Overall rank by patents
#6,681
of 50,000 tracked assignees
USPTO PatentsView assignee record - 50 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
According to USPTO PatentsView, Neurocrine ranks #6,681 of 50,000 tracked US assignees by granted-patent volume, with 50 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R6681 · US Corporation #6,681 · 50 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Navajo Manufacturing Company, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Canon Information An… · near
37 score
Crinetics Pharmaceut… · near
37 score
Legacy Ventures · near
37 score
Neurocrine Biosciences · this assignee
37 score
Nippon Micrometal · near
37 score
3D Lighting Innovati… · lowest
7 score
What this shows Neurocrine Biosciences, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-DENSE, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #6,681 of 50,000; Innovation Score 37.3/100 sits in the top 44% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Navajo Manufacturing Company, Inc. (±0 grants).
Neurocrine Biosciences, Inc. has been granted 50 US utility patents between 2015 and 2025, placing Neurocrine Biosciences, Inc. at #6,681 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Neurocrine Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Neurocrine sits between Ningbo Institute OF Materials Technology & Engineering, Chinese Academy OF Sciences (50 patents, rank #6,679) and OMAX Corporation (50 patents, rank #6,687) - the closest US assignees by grant volume. The composite Innovation Score of 37.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 34 grants, compared with 13 in the 2015–2019 window, a +162% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Neurocrine Biosciences, Inc.'s 20.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 6 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NINGBO INSTITUTE OF MATERIALS TECHNOLOGY & ENGINEERING, CHINESE ACADEMY OF SCIENCES
50 patents
NIPPON SHINYAKU CO., LTD.
50 patents
NUC Electronics Co., Ltd.
50 patents
Navajo Manufacturing Company, Inc.
50 patents
Nguyen Gaming LLC
50 patents
Northrop Grumman Innovation Systems, Inc.
50 patents
OCEAN'S KING LIGHTING SCIENCE & TECHNOLOGY CO., LTD.
50 patents
OMAX Corporation
50 patents
Neurocrine Biosciences, Inc.
50 patents
What this shows Neurocrine holds 50 patents at rank #6,683, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,683 in granted patent volume.
Other assignees with the most granted patents in Neurocrine's primary technology class.
Two PlainPatent-derived peer sets for Neurocrine, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (37 here).
Nearest assignees by average claims per patent (20.1 here).
Neurocrine's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
37 Top 44% higher than 56% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 2.0% |
| 2016 | 2 | 4.0% |
| 2017 | 3 | 6.0% |
| 2018 | 5 | 10.0% |
| 2019 | 2 | 4.0% |
| 2020 | 7 | 14.0% |
| 2021 | 16 | 32.0% |
| 2022 | 4 | 8.0% |
| 2023 | 4 | 8.0% |
| 2024 | 3 | 6.0% |
| 2025partial year | 3 | 6.0% |
Top 6 of 6 technology areas
Overall rank by patents
#6,681
of 50,000 tracked assignees
37.3 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.